Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

Lisa Murdock | Image Credit: American Diabetes Association

Roughly 500,000 Medicaid beneficiaries with 

 are predicted to lose healthcare coverage by 2034, according to a recent study from the American Diabetes Association (ADA).

According to the National Diabetes Statistics Report, released by the US Centers for Disease Control and Prevention (CDC), >40 million Americans have diabetes – of these, >29 million adults and children have a confirmed diabetes diagnosis. Roughly 6 million Americans with this diagnosis are enrolled in Medicaid, representing nearly 11% of the country’s total diabetes population. Additionally, approximately 1.7 million patients with diabetes are enrolled in an individual market plan via the Affordable Care Act (ACA).

However, in July 2025, Congress passed H.R. 1 legislation, which brought about significant changes to federal healthcare coverage through Medicaid. These policies are expected to reduce Medicaid enrollment by around 7 million beneficiaries by 2034. The document itself limits provider taxes states use to fund Medicaid programs, as well as increasing eligibility verification requirements and cost-sharing obligations for certain enrollees. Coupled with existing regulations, this legislation may revoke coverage for between 8 and 12 million patients in individual market plans.

“The extreme loss of healthcare coverage we’re anticipating among the diabetes population as a result of recent changes to the Medicaid program will have a devastating impact on people with diabetes and lasting repercussions across the US healthcare system—driven by increased hospitalizations, complications from diabetes, and emergency room care,” Lisa Murdock, chief advocacy officer of the ADA, said in a statement.

For the present study, the ADA commissioned research from Health Management Associates (HMA) to determine the scale of individual market coverage losses and new costs for Medicaid and ACA healthcare for patients with diabetes after the enactment of H.R. 1. Using Congressional Budget Office analysis and Medicaid enrollment and claims data, among other data sources, the ADA ultimately confirmed that, without further policy change, almost 500,000 Medicaid beneficiaries with diabetes will lose coverage by 2034.

The largest contributor to this reduction will be changes to state provider taxes, accounting for nearly 45% of projected disenrollments. Policies limiting erroneous payments (16%), more routine eligibility assessments (16%), and retroactive enrollment (12%) will also account for coverage losses over this period. Additionally, these data indicate that most patients who will lose their Medicaid coverage live in states that previously expanded their Medicaid programs under the ACA, accounting for 93% of projected disenrollments.

Of the patients who remain covered and enrolled in Medicaid, 1.5 million could have new cost-sharing obligations by 2029 – patients with diabetes could pay up to $1000 more annually for their health expenses. Additionally, 654,000 patients enrolled in ACA individual market plans are expected to lose coverage between 2025 and 2027, representing between 24% and 39% of all patients with diabetes who have ACA plans.

 stating that patients with low incomes who lack consistent healthcare coverage see poorer blood glucose management and need more medications, such as insulin, for long-term disease management compared to patients who do not regularly experience lapses in coverage. The resulting worse health outcomes could increase the likelihood of unnecessary hospitalizations. Therefore, the study concludes that limiting or eliminating coverage for some of the more vulnerable patients with diabetes could put a major burden on the US healthcare system, as well as patients with diabetes and their families.

“For half a million people with diabetes, losing access to Medicaid means losing access to healthcare professionals, diabetes education and management, affordable insulin, and technology critical to blood glucose management directly affecting their health,” Murdock said.

American Diabetes Association. Impact of Recent Medicaid and Affordable Care Act Policy Changes on Health Insurance Coverage and Cost-Sharing for Americans with Diabetes. August 3, 2026. Accessed August 6, 2026. 

https://diabetes.org/sites/default/files/2026-07/Affordable%20Care%20White%20Paper%20FINAL.pdf

American Diabetes Association. New Study: 500,000 Americans with Diabetes Projected to Lose Medicaid Coverage by 2034. 

. August 3, 2026. Accessed August 6, 2026. 

https://www.prnewswire.com/news-releases/new-study-500-000-americans-with-diabetes-projected-to-lose-medicaid-coverage-by-2034--302840319.html

Articles

Recent federal policy changes to Medicaid and Affordable Care Act coverage are projected to substantially disrupt insurance continuity for Americans with diabetes. Modeling commissioned by the American Diabetes Association estimates nearly 500,000 Medicaid beneficiaries with diabetes will lose coverage by 2034, driven largely by constraints on state provider taxes and intensified eligibility and payment integrity requirements. Remaining enrollees may face increased cost-sharing, while sizable losses are also expected in ACA individual market plans. Coverage instability is anticipated to worsen glycemic outcomes and increase avoidable acute-care utilization.

Limits to provider taxes used to fund Medicaid programs, as well as increased eligibility requirements and cost-sharing obligations, may make insurance inaccessible.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

This page also hosts content previously published by EndocrinologyNetwork. 


Type 1 Diabetes

Type 2 Diabetes

500,000 Patients With Diabetes May Lose Healthcare Under New Medicaid Legislation

Meagen M. McCusker, MD, MS, serves as the medical director of Integrated Dermatology of Enfield & Simsbury in Connecticut.

McCusker said patients remember how they were made to feel more than the specific treatment they received.

Unlike Shahriari's planner mindset, McCusker embraced spontaneity and instinct when deciding to build her own practice.

McCusker encouraged women physicians to seek advice and support from female colleagues rather than facing career transitions alone.

Meagen McCusker, MD, MS, medical director of Integrated Dermatology of Enfield & Simsbury, discussed the emotional rewards of 

 and the different paths physicians take toward major career changes in a conversation with host Mona Shahriari, MD, associate clinical professor of dermatology at Yale School of Medicine, on the 

McCusker and Shahriari opened by reflecting on why dermatology remains such a fulfilling specialty, noting that visible improvement, such as clearing psoriasis or atopic dermatitis, creates an intimate bond between physician and patient.

Why This Dermatologist Trusted Instinct Over a Backup Plan

McCusker said that patients tend to remember how they were made to feel more than the specific treatment provided, and that this emotional connection, along with loyalty among staff, is central to building a successful practice.

Do Physicians Need a Backup Plan Before Making a Career Change?

The conversation shifted to how physicians approach major transitions, such as leaving academic medicine to start a private practice. Shahriari described herself as a planner who prefers a clear backup strategy before making big decisions.

McCusker said her own approach was more spontaneous, explaining that she committed to building her own practice before working out every detail, trusting instinct over a rigid plan. She said that embracing some uncertainty ultimately motivated her to follow through.

Why Female Physicians Should Lean on Each Other During Career Transitions

Asked for advice for physicians who feel pressure to have everything perfectly prepared before taking a professional leap, McCusker pointed to the value of female mentorship. She said women in medicine are sometimes less likely to seek career advice from one another due to a perceived sense of competition.

McCusker also encouraged listeners to ask trusted female colleagues to review their work or offer guidance. She said women often understand how to build each other's confidence and can offer a different, valuable perspective during moments of uncertainty.

Editor’s note: Neither speaker had any relevant disclosures of note. This episode was summarized with the help of AI tools.

Shahriari M, McCusker M. The Medical Sisterhood: From Employee to Entrepreneur, With Meagen McCusker, MD. HCPLive. July 28, 2026. Accessed August 6, 2026. 

https://www.hcplive.com/view/medical-sisterhood-employee-entrepreneur-meagen-mccusker-md

Videos

Meagen McCusker, MD, discusses trusting instinct over rigid planning and why female physicians should lean on each other during career transitions.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Podcasts

podcasts page features a feed of medical news and interview podcast series, including DocTalk, Lungcast, Derm Discussions, and Heart Trials.

Physician and CEO, Chicago Allergy Center, and board director at American Lung Association

 vaccination rates remain low even as the virus settles into a predictable twice-a-year pattern. In this 

 interview, allergist Juanita Mora, MD, unpacks the American Lung Association's COVID-19 prevention campaign, including who qualifies for a booster now, an underused antiviral prophylaxis option, and the specialist's role in closing persistent vaccination gaps.

ALA: Why COVID-19 Boosters Matter Now, With Juanita Mora, MD

COVID-19 antiviral use remains under 15%, and adult vaccination rates were only ~18% this past season

High-risk groups (age 65+, chronic lung/heart/kidney disease, diabetes, immunocompromised) should consider a summer booster, since antibody protection lasts about 6 months

Antiviral prophylactic treatment is available for high-risk adults and immunocompromised children 12 and older

Specialists can help close vaccination gaps by reviewing COVID-19, flu, and RSV status at every visit

Patients can check eligibility for the updated COVID-19 vaccine at lung.org

Our vaccination rates have been low throughout the country for COVID-19 vaccinations, and I think out of sight is out of mind for a lot of people. Many people [feel] we're done with the pandemic, so we don't have to worry about COVID 19 anymore. What I tell patients though is COVID 19 has become like the flu; it's coming back every season. It's here to stay.

COVID-19 vaccination rates among adults remain low even as the virus has settled into a predictable, twice-yearly seasonal pattern. According to CDC data cited in the American Lung Association's recently launched prevention campaign, only 18% of adults received a COVID-19 vaccine during the 2025–26 respiratory virus season — dropping to 31% among adults aged 65–74 and 37% among those 75 and older, the groups at highest risk for severe disease and hospitalization.1 Antiviral treatment is similarly underutilized: use remains below 15% among eligible patients, and only 16% receive treatment within the recommended 5-day window from symptom onset.1

Mora, of Chicago Allergy Center, and a medical expert spokesperson for the American Lung Association, spoke with 

 about the campaign and what specialist clinicians can do to close those gaps in their own practices.

COVID-19 has evolved from a pandemic threat into a predictable endemic respiratory virus — one that now circulates in 2 distinct seasonal waves per year, much like influenza and RSV. That shift has direct implications for how clinicians should counsel patients about booster timing. Vaccine-induced antibody protection against severe disease typically wanes over approximately 6 months, meaning the twice-yearly pattern of circulation aligns closely with the protection window from a single vaccine dose. For high-risk patients — those aged 65 and older, and those with chronic lung disease (including asthma, COPD, interstitial lung disease, cystic fibrosis, and pulmonary hypertension), heart disease, diabetes, chronic kidney disease, or immunocompromising conditions — a summer booster is a clinically reasonable consideration even if they received the fall/winter vaccine. Adults 65 and older are now formally recommended to receive 2 doses of the 2025–26 COVID-19 vaccine at least 6 months apart.1

Beyond vaccination, the ALA campaign highlights 2 prophylactic options that remain largely unknown to patients and underutilized even among clinicians. Ensitrelvir is an oral antiviral approved for post-exposure prophylaxis in individuals aged 12 and older who have had close contact with a COVID-19-positive person. It is taken over 5 days, with 3 tablets on day 1 and 1 tablet on days 2 through 5. Pemivibart is an intravenous monoclonal antibody approved for pre-exposure prophylaxis in moderately or severely immunocompromised patients for whom vaccination is likely to be insufficient. Both options represent an underappreciated layer of protection for high-risk populations who may not mount adequate vaccine responses or who face particularly high consequences from breakthrough infection.1

For specialists — pulmonologists, allergists, rheumatologists, cardiologists, and others managing patients with the chronic conditions that confer high COVID-19 risk — Mora emphasized that every clinical encounter represents an opportunity to address vaccination status comprehensively. Reviewing COVID-19, flu, and RSV vaccination status at each visit, correcting misconceptions about whether COVID-19 vaccines are still needed, and directing patients to the ALA's eligibility checker at lung.org are all actionable steps that do not require adding time to an already compressed appointment.

Editor’s note: Mora has no relevant disclosures to report.

American Lung Association. American Lung Association highlights therapeutic options available to prevent and treat COVID-19 [press release]. July 30, 2026. 

https://www.prnewswire.com/news-releases/american-lung-association-highlights-therapeutic-options-available-to-prevent-and-treat-covid-19-302835975.html

American Lung Association. Prevent COVID-19. 

https://www.lung.org/lung-health-diseases/lung-disease-lookup/covid-19/prevention

COVID-19 vaccine uptake remains poor despite a now-endemic, twice-yearly circulation pattern resembling influenza/RSV. Only 18% of adults received a 2025–26 season dose, with modestly higher coverage in older high-risk groups; antiviral treatment is also underused and often delayed beyond five days. Antibody-mediated protection wanes around six months, supporting consideration of a summer booster for high-risk patients; adults ≥65 are recommended two 2025–26 doses six months apart. Additional prophylaxis includes ensitrelvir post-exposure and pemivibart pre-exposure for select immunocompromised patients.

Allergist Juanita Mora, MD, breaks down the ALA's COVID-19 prevention campaign — who needs a booster now, and how specialists can close the gap.

COVID-19

COVID-19 page, resources on the topics of medical news and expert insight into coronavirus can be found. Content includes articles, interviews, videos, podcasts, and breaking news on COVID-19 research, treatment, and drug development.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

Strategic Alliance Partnership

Merve Karaca Şahin, from University of Health Sciences, Prof. Dr. Cemil Tascioglu City Hospital in Istanbul, Turkey.

avoidant/restrictive food intake disorder (ARFID)

-related eating behaviors than healthy peers, driven primarily by picky eating and fear-based avoidance rather than appetite loss, according to a recent study.

 Food Allergy Linked to ARFID-Related Eating Behaviors in Children

Feeding difficulties in pediatric food allergy have been reported across a wide range, from 13.6% to 40%, but prior studies relied on heterogeneous terminology and diagnostic instruments and skewed toward non-IgE-mediated phenotypes.

No prior study had applied the Nine Item Avoidant/Restrictive Food Intake Disorder Screen–Parent Report (NIAS-PR) to an IgE-mediated food allergy population, leaving a gap in standardized data for allergists managing selective or avoidant eaters.¹

“Importantly, their appetite scores were similar to those of healthy children, so the main issue may not be low appetite,” Merve Karaca Şahin, from Prof. Dr. Cemil Tascioglu City Hospital in Istanbul, Turkey, told 

 “Instead, fear and picky eating may limit the foods children feel safe eating.”

NIAS-PR Scores and Eating Behavior Domains in Food Allergy

The single-center, prospective, controlled study enrolled 234 children aged 2 to 9 years, including 117 with physician-diagnosed food allergy and 117 age- and sex-matched healthy controls, evaluated at the Pediatric Immunology and Allergy Outpatient Clinic of University of Health Sciences, Prof. Dr. Cemil Tascioglu City Hospital between September 2025 and February 2026.¹ Parents completed the NIAS-PR, a validated tool assessing 3 domains: picky eating, appetite, and fear of aversive consequences from eating.¹

Median total NIAS-PR scores were significantly greater in the food allergy group than in controls (17 [IQR, 11-24] vs 12 [IQR, 7-18]; 

 <.001).¹ The difference was driven by picky eating and fear subscale scores (both 

 <.001), whereas appetite subscale scores did not differ significantly between groups (

 =.311).¹ Karaca Şahin said this pattern challenges assumptions that food allergy uniformly suppresses interest in eating, noting a child may enjoy eating yet restrict intake to a narrow list of foods perceived as safe.

Growth, Asthma, and Reaction Severity Tied to ARFID Risk

What did the NIAS-PR study find in children with food allergy?

Children with food allergy had significantly higher NIAS-PR total, picky eating, and fear subscale scores than healthy controls, while appetite scores did not differ.

Does food allergy suppress appetite in children?

Not according to this study; appetite-related items were similar between children with food allergy and controls, suggesting fear and picky eating, not appetite loss, drive ARFID-related behavior.

When should a positive ARFID screen prompt referral in children with food allergy?


Karaca Şahin recommends referral when restriction is accompanied by faltering growth, weight loss, a narrow food list, persistent fear, or difficulty reintroducing tolerated foods, rather than from the score alone.

Children with food allergy also demonstrated significantly lower weight-for-age (−0.20 ± 1.10 vs 0.26 ± 1.05; 

 =.001) and height-for-age z-scores (−0.40 ± 1.18 vs 0.15 ± 1.18; 

 <.001) compared with controls. BMI z-scores did not differ significantly between groups (

 =.117).¹ Karaca Şahin said the study could not separate how much of this growth difference stemmed from ARFID-related behaviors versus the elimination diet itself, calling the effect likely multifactorial given the absence of detailed dietary intake data.

Within the food allergy group, children with comorbid asthma (n = 34) had greater total NIAS-PR scores than those without asthma (19 [IQR, 14-39] vs 16 [IQR, 10-22]; 

 =.043).1 Karaca Şahin cautioned against overinterpreting the modest link, noting that the study was not designed to explain the association and that, for now, it should be viewed as an intriguing lead for future research. Children with a history of urticaria (

 =.014) also scored significantly greater on the fear subscale.

“This makes sense clinically because anaphylaxis can be life-threatening and very frightening, while urticaria is often sudden, visible, and memorable,” Karaca Şahin said. “These reactions make children and their families feel that eating is unsafe. Over time, this may lead to more food avoidance.”

Because no validated NIAS-PR cutoff exists for diagnosing ARFID in this population, Karaca Şahin said a positive screen alone should not trigger referral; instead, she flags faltering growth, weight loss, a very narrow food list, persistent fear, or difficulty reintroducing a food after a negative oral food challenge as signals warranting evaluation by feeding and mental health specialists.

Related Research on ARFID Risk in Pediatric Food Allergy

separate research showing children with and without food allergy screened positive for possible ARFID at similar rates

 (23% vs 21%) underscoring ongoing uncertainty about how allergy-specific this risk truly is.

 In a population-based Australian birth cohort study, possible ARFID among children with food allergy was more common in those with anaphylaxis or an epinephrine autoinjector prescription, and current hay fever was linked to greater rates of both possible ARFID and possible ARFID inclusive of food allergy anxiety.

Karaca Şahin M, Çalışkan N, Şarman HT, et al. Fear and picky eating-related ARFID behaviors in children with food allergy. 

Hill SA, Nurmatov U, DunnGalvin A, et al. Feeding difficulties in children with food allergies: An EAACI Task Force Report. 

Ciciulla D. Q&A: 1 in 5 children with food allergy screen positive for possible ARFID. HCPLive. Published August 6, 2026. Accessed August 6, 2026. 

https://www.hcplive.com/view/1-in-5-children-food-allergy-screen-positive-possible-arfid

A prospective controlled study of 234 children finds food allergy raises ARFID-related picky eating and fear scores, but not appetite loss.

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Food Allergy

Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

Food Allergy Linked to ARFID-Related Eating Behaviors in Children

Alex Hillenbrand is an assistant editor for 

. She earned her BA in English from Lafayette College in 2023 and went on to write for pop culture, entertainment, and sports media outlets before joining MJH Life Sciences in 2025. In her free time, Alex enjoys cooking, going on walks, and meeting new people. Contact her at mjhlifesciences.com.

and a discontinued development program in the same condition.

 granted priority review to Agios' mitapivat sNDA for 

, with a PDUFA date of November 1, 2026, which, if approved, would become the first oral pyruvate kinase activator for the condition. About 2 weeks later, Agios discontinued development of tebapivat, a separate pyruvate kinase activator, in sickle cell disease after phase 2 results did not show sufficient differentiation from placebo. HCPLive also spoke with Wendy Stock, MD, about the FDA's approval of Orca-T (Tregzi), a precision-engineered cell therapy for allogeneic transplant in adults with hematological malignancies.

Below is a summary of the July 2026 stories in hematology, covering regulatory decisions and trial data in sickle cell disease and cell therapy for transplant-related graft-versus-host disease.

FDA Grants Priority Review to Agios' Mitapivat sNDA for Sickle Cell Disease

On July 7, 2026, the FDA granted priority review to Agios' supplemental NDA for mitapivat, an oral pyruvate kinase activator, in sickle cell disease, with a PDUFA date set for November 1, 2026. Mitapivat is already approved in the US for two other hemolytic anemias, pyruvate kinase deficiency and thalassemia.

Agios Ends Tebapivat Development in Sickle Cell Disease After Phase 2

On July 21, 2026, Agios discontinued development of tebapivat in sickle cell disease after phase 2 results showed hemoglobin responses across active doses that were not sufficiently differentiated from placebo. The company said the decision was based on lack of differentiation rather than safety or tolerability concerns, and that it will continue to focus its sickle cell disease efforts on mitapivat.

FDA Approves Orca-T After Phase 3 Trial Improves Chronic GVHD-Free Survival

In this interview, Wendy Stock, MD, discusses the FDA approval of Orca-T (Tregzi), a precision-engineered allogeneic regulatory T-cell therapy for adults with hematological malignancies undergoing matched-donor transplant. The conversation covers phase 3 data showing improved chronic graft-versus-host disease-free survival compared with conventional allogeneic transplant, along with open questions on cost, longer-term relapse control, and how the therapy compares with existing GVHD prevention approaches

July brought divergent pyruvate kinase activator updates in sickle cell disease, with mitapivat advancing under FDA priority review and a November 1, 2026 PDUFA date, while tebapivat was discontinued after phase 2 efficacy failed to separate meaningfully from placebo. In transplant, FDA approval of Orca-T (Tregzi) for adults with hematologic malignancies undergoing matched-donor allogeneic transplant highlighted phase 3 evidence of improved chronic GVHD–free survival versus conventional approaches, alongside practical uncertainties around cost, durability, relapse risk, and positioning versus established GVHD prophylaxis.

Hematology in July 2026: FDA priority review for Agios' mitapivat in sickle cell disease, plus Orca-T's approval for GVHD-free survival.

Hematology

FDA News

Sickle Cell

Sickle Cell condition center page, resources on the topics of medical news and expert insight into sickle cell disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on sickle cell research, treatment, and drug development.

3 Hematology Headlines You Missed in July 2026

Diana Isaacs, PharmD, is an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic.

In this segment from the latest episode of Diabetes Dialogue, Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss topline data from the TRIUMPH-3 trial of retatrutide.

Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

Retatrutide Cuts Weight, Cardiovascular Disease Risk in TRIUMPH-3

Victoria Johnson joined MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and is now an assistant managing editor for HCPLive and RheumatologyLive. She doesn’t have enough time for her numerous hobbies. You can reach her at vjohnson@mjhlifesciences.com.

Merck's sBLA seeks to extend clesrovimab-cfor (Enflonsia) coverage to children under 2 years at increased risk for severe RSV during their second season.

Infectious Disease

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on viruses, infections, and bacteria. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for COVID-19, influenza, vaccine-preventable diseases, and more.

Pediatrics

Pediatrics page, resources on the topics of medical news and expert insight into childhood health care can be found. Content includes articles, interviews, videos, podcasts, and breaking news on pediatric disease research, treatment, and drug development.

FDA Accepts sBLA for Clesrovimab-cfor in Second RSV Season

Stacey Rifkin-Zenenberg, DO, is a Pediatric Hematologist Oncologist in Hackensack, NJ. She has 30 years of experience and is board certified in Hospice Care and Palliative Medicine.

Stacey Rifkin-Zenenberg, DO, on gene therapy vs stem cell transplant and when to refer for sickle cell disease. 

With 2 Curative Pathways, Sickle Cell Intervention Can Start in Infancy

Linda Stein Gold, MD, is a dermatologist at Henry Ford Health. 

Linda Stein Gold, MD, discusses age-stratified ADORING data on tapinarof cream for atopic dermatitis, presented at the 2026 SPD Annual Meeting.

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

Age-Stratified ADORING Data Show Consistent Tapinarof Efficacy in Eczema

Chelsie Derman is an associate editor for 

who covers allergy and  psychiatry. She joined MJH Life Sciences in September 2023 after graduating from The College of New Jersey with a bachelor’s degree in journalism and professional writing. In her free time, she enjoys creative writing and reading.

The mRNA-based vaccine wins full approval for adults aged 50 to 64 years and accelerated approval for adults aged ≥ 65 years following unanimous VRBPAC backing.

mFLUSIVA Receives FDA Approval for Influenza in Adults 50 and Older

Combination therapy with navepegritide and lonapegsomatropin has demonstrated its efficacy in improving mean annualized growth velocity in pediatric patients.

Hormonal Disorders

Ascendis Reports 78-Week Data From COACH Trial for Achondroplasia

Saakshi Khattri, MD, is a board certified Dermatologist, Rheumatologist and Internist and one of only a handful of triple board-certified physicians across the US.

Saakshi Khattri, MD, discusses the comparable safety profile of risankizumab in psoriasis and psoriatic arthritis and the minimal need for routine laboratory monitoring.

Video Series

Consistent Safety Profile of Risankizumab Across Psoriasis and Psoriatic Arthritis

Mandana Khalili, MD, is Chief of Clinical Hepatology and Director of Clinical and Translational Research in Hepatology at San Francisco General Hospital, and directs the UCSF T32 Hepatology Training Program.

Mandana Khalili, MD, discusses how baseline motivation predicted alcohol reduction in a stepped treatment trial for liver disease patients.

Hepatology

Baseline Motivation Predicts Alcohol Reduction in Chronic Liver Disease

Linda Stein Gold, MD, discusses ADORING trial endpoints and remaining treatment gaps in the youngest patients with atopic dermatitis.

Q&A: Tapinarof Data Highlight Unmet Pediatric Needs in Atopic Dermatitis

Friedman breaks down the updated CSU guidelines and where omalizumab, dupilumab, and remibrutinib fit.

Urticaria

The HCPLive urticaria page is a comprehensive resource for clinical news and insights on chronic idiopathic urticaria and chronic spontaneous urticaria. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for urticaria, and more.

Latest News

500,000 Patients With Diabetes May Lose Healthcare Under New Medicaid Legislation

Why This Dermatologist Trusted Instinct Over a Backup Plan

ALA: Why COVID-19 Boosters Matter Now, With Juanita Mora, MD

Food Allergy Linked to ARFID-Related Eating Behaviors in Children

3 Hematology Headlines You Missed in July 2026